20 years of taxane therapy in prostate cancer – the past, present and future.
This review highlights the twentieth anniversary of FDA approval of docetaxel for advanced prostate cancer, marking a si...
[Therapy Management of PARP Inhibitor Combinations in mCRPC Clinical Practice].
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
This publication reviews the use of poly(ADP-ribose) polymerase inhibitors (PARPi) combined with androgen receptor inhib...
P21-positive senescent stromal cells promote prostate cancer immune suppression and progression that can be reversed by senolytic therapy.
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
This study investigates the role of cellular senescence in prostate cancer progression, focusing on p16+ and p21+ senesc...
Autocatalytic Signal Amplification via Orthogonal Recognition of Dual Proteins on the Surface of Serum Extracellular Vesicles for Precise Diagnosis of Prostate Cancer.
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
This study presents a novel dual-protein orthogonal triggered autocatalytic signal amplification (DOTASA) strategy to im...
[Options in nuclear medicine for advanced prostate cancer in practice].
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
This publication reviews recent advances in prostate-specific membrane antigen (PSMA) positron emission tomography/compu...
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
The AMPLITUDE trial investigated the efficacy of adding niraparib, a PARP inhibitor, to abiraterone acetate and predniso...